GSK's Momelotinib Receives Orphan Drug Designation From FDA And European Medicines Agency For VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) Syndrome

Loading news article.

GSK's Momelotinib Receives Orphan Drug Designation From FDA And European Medicines Agency For VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) Syndrome | WAPE

GSK's Momelotinib Receives Orphan Drug Designation From FDA And European Medicines Agency For VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) Syndrome

Article summary

Related companies

Comments —